Literature DB >> 7548819

Management of symptomatic polycystic liver disease: laparoscopy adjuvant with alcohol sclerotherapy.

K S Jeng1, F S Yang, C R Kao, S H Huang.   

Abstract

An 81 year old woman with extensive polycystic liver disease received laparoscopic unroofing and fenestration, followed by 95% ethanol sclerotherapy, resulting in almost complete disappearance of the cysts. Such a procedure can avoid complications of both the multi-segmental liver resections and extensive fenestrations, and untoward reactions from a large amount of alcohol. In addition, it can achieve a satisfactory result. It is suggested that this procedure could be a safe and effective alternative to traditional open surgery in selective patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7548819     DOI: 10.1111/j.1440-1746.1995.tb01109.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  Laparoscopic management of benign liver diseases: where are we?

Authors:  Jean-François Gigot; Catherine Hubert; Radu Banice; Michael L Kendrick
Journal:  HPB (Oxford)       Date:  2004       Impact factor: 3.647

2.  Percutaneous sclerotherapy of renal cysts with a beta-emitting radionuclide, holmium-166-chitosan complex.

Authors:  Joo Hee Kim; Jong Tae Lee; Eun Kyung Kim; Jong Yoon Won; Myeong-Jin Kim; Jong Doo Lee; Sung Joon Hong
Journal:  Korean J Radiol       Date:  2004 Apr-Jun       Impact factor: 3.500

3.  A Case of Post-Traumatic Pseudocyst in the Spleen Successfully Treated with Alcohol Sclerotherapy.

Authors:  Sang Wook Mun; Taek-Jin Lim; Eun Ha Hwang; Yeoun Joo Lee; Ung Bae Jeon; Jae Hong Park
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2015-12-23

4.  Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis.

Authors:  Lucas H P Bernts; Sebastiaan G Echternach; Wietske Kievit; Camiel Rosman; Joost P H Drenth
Journal:  Surg Endosc       Date:  2018-10-17       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.